Literature DB >> 31400520

Caring for the pregnant woman with an inherited arrhythmia syndrome.

Thomas M Roston1, Christian van der Werf2, Christopher C Cheung3, Jasmine Grewal3, Brianna Davies3, Arthur A M Wilde2, Andrew D Krahn4.   

Abstract

Pregnancy is a period of increased cardiovascular risk in a woman's life. In the setting of an inherited arrhythmia syndrome (IAS), cardiologists and obstetricians may be unfamiliar with cardiovascular optimization and risk stratification in pregnancy. Historically, there were little data addressing the safety of pregnancy in these rare disorders. Recent advances suggest that no type of IAS represents an absolute contraindication to pregnancy. However, it is imperative that obstetric and cardiovascular clinicians understand the major forms of IAS and how they affect the risks and course of pregnancy. This includes any disease-specific proarrhythmic triggers unique to pregnancy, such as the postpartum period in long QT syndrome (especially type 2), which poses the greatest risk of arrhythmias, and the adrenergic nature of labor and delivery, which is relevant to catecholaminergic polymorphic ventricular tachycardia. Fortunately, several effective antiarrhythmic options exist that pose little fetal risk. IAS-specific optimization of implantable cardioverter-defibrillator algorithms, drug therapy, and a maternal cardiac plan addressing the antepartum, labor, and delivery and postpartum periods reduces the risk. Where evidence does not exist, there are plausible mechanistic considerations to guide clinicians. To achieve optimal outcomes, early involvement of an expert pregnancy heart team comprising obstetrics, genetics, cardiology, and anesthesiology team members and a shared decision-making approach to IAS issues in pregnancy are needed.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Channelopathy; Inherited arrhythmia; Pregnancy; Sudden cardiac death; long QT syndrome

Mesh:

Substances:

Year:  2019        PMID: 31400520     DOI: 10.1016/j.hrthm.2019.08.004

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  6 in total

Review 1.  Pregnancy in patients with implantable cardiac defibrillators.

Authors:  Geoffrey R Wong; Megan Ang; Jasveer Jayarajan; Fiona Walker; Pier D Lambiase
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-05-10

Review 2.  Pregnancy in catecholaminergic polymorphic ventricular tachycardia: therapeutic optimization and multidisciplinary care are key to success.

Authors:  Thomas M Roston; Jasmine Grewal; Andrew D Krahn
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-04-21

3.  Ivabradine use in pregnant women-treatment indications and pregnancy outcome: an evaluation of the German Embryotox database.

Authors:  Maria Hoeltzenbein; Marie-Louise Lehmann; Evelin Beck; Katarina Dathe; Christof Schaefer
Journal:  Eur J Clin Pharmacol       Date:  2021-01-26       Impact factor: 2.953

4.  Catecholaminergic polymorphic ventricular tachycardia in pregnancy: a case report.

Authors:  Amy Schumer; Stephen Contag
Journal:  J Med Case Rep       Date:  2020-12-09

Review 5.  Management of Congenital Long-QT Syndrome: Commentary From the Experts.

Authors:  Lee L Eckhardt; Elizabeth S Kaufman; Michael J Ackerman; Peter F Aziz; Elijah R Behr; Marina Cerrone; Mina K Chung; Michael J Cutler; Susan P Etheridge; Andrew D Krahn; Steven A Lubitz; Marco V Perez; Silvia G Priori; Jason D Roberts; Dan M Roden; Eric Schulze-Bahr; Peter J Schwartz; Wataru Shimizu; M Benjamin Shoemaker; Raymond W Sy; Jeffrey A Towbin; Sami Viskin; Arthur A M Wilde; Wojciech Zareba
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-07-09

Review 6.  Successful treatment of arrhythmia with β-blocker and flecainide combination in pregnant patients with Andersen-Tawil syndrome: A case report and literature review.

Authors:  Pongprueth Rujirachun; Apichaya Junyavoraluk; Manop Pithukpakorn; Bhoom Suktitipat; Arjbordin Winijkul
Journal:  Ann Noninvasive Electrocardiol       Date:  2020-09-21       Impact factor: 1.468

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.